Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will earn $1.88 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 target price on the stock. Finally, Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $21.57.

Zevra Therapeutics Trading Down 0.6 %

NASDAQ:ZVRA traded down $0.05 on Thursday, reaching $8.10. 394,429 shares of the stock traded hands, compared to its average volume of 404,538. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The company's 50 day moving average is $8.66 and its 200-day moving average is $7.83. The firm has a market capitalization of $432.38 million, a price-to-earnings ratio of -4.11 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the firm posted ($0.40) earnings per share.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its holdings in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC bought a new position in Zevra Therapeutics in the 3rd quarter valued at $92,000. XTX Topco Ltd purchased a new position in Zevra Therapeutics during the third quarter worth about $94,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $95,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.